Pneumococcal infection in adults: Burden of disease

Clinical Microbiology and Infection

Volumn 20, Issue S5, 2014, Pages 45-51

  Drijkoningen, J J C ^a   Rohde, G G U ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Community acquired pneumonia; Disease burden; Elderly; Incidence; Invasive pneumococcal disease; Outcome; Pneumococcal conjugate vaccine; Pneumococcal pneumonia; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; VACCINE;

ADULT DISEASE; AGED; COMMUNITY ACQUIRED PNEUMONIA; ECONOMIC ASPECT; GERIATRIC DISORDER; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SEROTYPE; ADULT; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; ECONOMICS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

STREPTOCOCCUS PNEUMONIAE;

ADULT; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; HUMANS; INCIDENCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84897544513     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12461     Document Type: Review

References (77)

1. Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012; 21: 57-65.
2. Sanz Herrero F, Blanquer Olivas J. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit care Med 2012;33:220-231.
3. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011; 17(suppl 6): E1-E59.
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79.
5. Said MA, Johnson HL, Nonyane BA et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE 2013; 8: e60273.
6. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis 2013; 32: 305-316.
7. Cilloniz C, Ewig S, Polverino E et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 2012; 40: 931-938.
8. Klapdor B, Ewig S, Pletz MW et al. Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J 2012; 39: 1156-1161.
9. Ewig S, Klapdor B, Pletz MW et al. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax 2012; 67: 132-138.
10. Almirall J, Bolibar I, Vidal J et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15: 757-763.
11. Jokinen C, Heiskanen L, Juvonen H et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977-988.
12. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia England. Emerg Infect Dis 2008; 14: 727-733.
13. Schnoor M, Hedicke J, Dalhoff K, Raspe H, Schafer T, group Cs. Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect 2007;55:233-239.
14. Marston BJ, Plouffe JF, File TM Jr et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157:1709-1718.
15. Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents 2011; 38: 108-117.
16. Froes F, Diniz A, Mesquita M, Serrado M, Nunes B. Hospital admissions of adults with community-acquired pneumonia in Portugal between 2000 and 2009. Eur Respir J 2013; 41: 1141-1146.
17. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369: 155-163.
18. Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit care Med. 2009;30:179-188.
19. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-141.
20. Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013; 68: 571-579.
21. Kalin M, Ortqvist A, Almela M et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840-847.
22. Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit care Med 2009; 30: 127-135.
23. Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
24. Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, Brock GN, authors C. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2013;107:1101-1111.
25. Ruhnke GW, Coca-Perraillon M, Kitch BT, Cutler DM. Trends in mortality and medical spending in patients hospitalized for community-acquired pneumonia: 1993-2005. Med Care 2010; 48: 1111-1116.
26. Restrepo MI, Faverio P, Anzueto A. Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis 2013; 26: 151-158.
27. Bruns AH, Oosterheert JJ, Cucciolillo MC et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect 2011; 17: 763-768.
28. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM. Pneumonia mortality in a UK general practice population cohort. Eur J Pub Health 2009; 19: 521-526.
29. Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285: 1729-1735.
30. Centers for Disease Control and Prevention. 2013. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2011. [Internet]. 2013.
31. Kyaw MH, Christie P, Clarke SC et al. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 2003; 37: 1283-1291.
32. Reinert RR, Haupts S, van der Linden M et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect 2005; 11: 985-991.
33. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit care Med 2009; 30: 189-209.
34. Hung IF, Tantawichien T, Tsai YH, Patil S, Zotomayor R. Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. Int J Infect Dis 2013; 17: e364-e373.
35. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31: 501-508.
36. Myint TT, Madhava H, Balmer P et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013; 30: 127-151.
37. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11: 760-768.
38. Burgos J, Falco V, Borrego A et al. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clin Microbiol Infect 2013; 19: 385-391.
39. Muhammad RD, Oza-Frank R, Zell E et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis 2013; 56: e59-e67.
40. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003; 187: 1424-1432.
41. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002; 35: 547-555.
42. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011 (1.). Emerg Infect Dis 2013; 19: 1074-1083.
43. Kaplan SL, Barson WJ, Lin PL et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32: 203-207.
44. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107: 34S-43S.
45. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-229.
46. Rock C, Sadlier C, Fitzgerald J et al. Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center. Eur J Clin Microbiol Infect Dis 2013; 32: 1135-1141.
47. Thomas K, Mukkai Kesavan L, Veeraraghavan B et al. Invasive pneumococcal disease associated with high case fatality in India. J Clin Epidemiol 2013;66:36-43.
48. Song JY, Choi JY, Lee JS et al. Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study. BMC Infect Dis 2013; 13: 202.
49. Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
50. Tsigrelis C, Tleyjeh IM, Lahr BD, Nyre LM, Virk A, Baddour LM. Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995-2007: a population-based study. Clin Infect Dis 2008; 47: 1367-1371.
51. Pulido M, Sorvillo F. Declining invasive pneumococcal disease mortality in the United States, 1990-2005. Vaccine. 2010; 28: 889-892.
52. Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294: 2043-2051.
53. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009; 374: 1196-1208.
54. Butler JC, Schuchat A. Epidemiology of pneumococcal infections in the elderly. Drugs Aging 1999; 15(Suppl 1): 11-19.
55. Fung HB, Monteagudo-Chu MO. Community-acquired pneumonia in the elderly. Am J Geriatr Pharmacother 2010; 8: 47-62.
56. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F, Group ES. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med 2009; 103: 309-316.
57. Cilloniz C, Polverino E, Ewig S et al. Impact of Age and Comorbidity on Etiology and Outcome in Community-Acquired Pneumonia. Chest 2013; 144: 999-1007.
58. Jackson ML, Neuzil KM, Thompson WW et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39: 1642-1650.
59. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005; 294: 2712-2719.
60. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010; 28: 4955-4960.
61. Kothe H, Bauer T, Marre R et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32: 139-146.
62. El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163(3 Pt 1): 645-651.
63. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46: 1078-1084.
64. Huang SS, Johnson KM, Ray GT et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011; 29: 3398-3412.
65. Gibson GJ, Loddenkemper R, Sibille Y. European lung white book. 2 edn. Sheffield, UK: European Respiratory Society/European Lung Foundation, 2003.
66. Bauer TT, Welte T, Ernen C et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005; 128: 2238-2246.
67. Bartolome M, Almirall J, Morera J et al. A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J 2004; 23: 610-616.
68. Sicras-Mainar A, Ibanez-Nolla J, Cifuentes I, Guijarro P, Navarro-Artieda R, Aguilar L. Retrospective epidemiological study for the characterization of community-acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain). BMC Infect Dis 2012; 12: 283.
69. De Graeve D, Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 2004; 22: 719-740.
70. Wroe PC, Finkelstein JA, Ray GT et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis 2012; 205: 1589-1592.
71. Kozma CM, Dickson M, Raut MK et al. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP). J Med Econ 2010; 13: 719-727.
72. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A, Group ES. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study. Hum Vaccin Immunother 2012; 8: 639-644.
73. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect 2012; 18(Suppl 5): 7-14.
74. Elemraid MA, Rushton SP, Shirley MD et al. Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia. Epidemiol Infect 2012; 141: 1697-1704.
75. Paradiso PR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis 2012; 55: 259-264.
76. Hak E, Grobbee DE, Sanders EA et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66: 378-383.
77. Durando P, Alicino C, De Florentiis D, Martini M, Icardi G. Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine. J Prev Med Hyg 2012; 53: 68-77.